FTC report finds PBMs profit at the expense of patients and independent pharmacies

Taking stock of the drug industry, from the lab to the medicine chest

July 9, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | FTC report finds PBMs profit at the expense of patients and independent pharmacies The FTC, in a report released Tuesday, says the big PBMs exercise significant control over which drugs are available, their price and access to them. By Ed Silverman STAT+ | Mikael Dolsten, Pfizer CSO who could take on Covid but not Wall Street, to step down Dolsten helped Pfizer outrace Moderna in the bid to develop a Covid vaccine but struggled to deliver on the expectations of its investors. By Matthew Herper STAT+ | Drugmakers are losing crucial friends on Capitol Hill Six pharma-friendly lawmakers will likely not be on Capitol Hill in 2025. Experts say their replacements may not be as receptive to drug industry lobbying. By Rachel Cohrs Zhang Mario Tama/Getty Images STAT+ | South Africa and J&J reach a deal to widen access to a key tuberculosis treatment The arrangement is significant because the drug, bedaquiline, is a backbone of combination therapies for treating multidrug-resistant tuberculosis. By Ed Silverman STAT+ | Opinion: Private equity and neuroscience: a novel approach to developing new treatments for neurological disorders First Opinion essay: Recent deals involving Karuna Therapeutics, Cerevel Therapeutics show market opportunities for private equity in neurological field. By Bruce Leuchter

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser